



metachromatic leukodystrophy

Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. This accumulation especially affects cells in the nervous system that produce myelin, the substance that insulates and protects nerves. Nerve cells covered by myelin make up a tissue called white matter. Sulfatide accumulation in myelin-producing cells causes progressive destruction of white matter (leukodystrophy) throughout the nervous system, including in the brain and spinal cord (the central nervous system) and the nerves connecting the brain and spinal cord to muscles and sensory cells that detect sensations such as touch, pain, heat, and sound (the peripheral nervous system).

In people with metachromatic leukodystrophy, white matter damage causes progressive deterioration of intellectual functions and motor skills, such as the ability to walk. Affected individuals also develop loss of sensation in the extremities (peripheral neuropathy), incontinence, seizures, paralysis, an inability to speak, blindness, and hearing loss. Eventually they lose awareness of their surroundings and become unresponsive. While neurological problems are the primary feature of metachromatic leukodystrophy, effects of sulfatide accumulation on other organs and tissues have been reported, most often involving the gallbladder.

The most common form of metachromatic leukodystrophy, affecting about 50 to 60 percent of all individuals with this disorder, is called the late infantile form. This form of the disorder usually appears in the second year of life. Affected children lose any speech they have developed, become weak, and develop problems with walking (gait disturbance). As the disorder worsens, muscle tone generally first decreases, and then increases to the point of rigidity. Individuals with the late infantile form of metachromatic leukodystrophy typically do not survive past childhood.

In 20 to 30 percent of individuals with metachromatic leukodystrophy, onset occurs between the age of 4 and adolescence. In this juvenile form, the first signs of the disorder may be behavioral problems and increasing difficulty with schoolwork. Progression of the disorder is slower than in the late infantile form, and affected individuals may survive for about 20 years after diagnosis.

The adult form of metachromatic leukodystrophy affects approximately 15 to 20 percent of individuals with the disorder. In this form, the first symptoms appear during the teenage years or later. Often behavioral problems such as alcoholism, drug abuse, or difficulties at school or work are the first symptoms to appear. The affected individual may experience psychiatric symptoms such as delusions or hallucinations. People with the adult form of metachromatic leukodystrophy may survive for 20 to 30 years after

diagnosis. During this time there may be some periods of relative stability and other periods of more rapid decline.

Metachromatic leukodystrophy gets its name from the way cells with an accumulation of sulfatides appear when viewed under a microscope. The sulfatides form granules that are described as metachromatic, which means they pick up color differently than surrounding cellular material when stained for examination.

Frequency

Metachromatic leukodystrophy is reported to occur in 1 in 40,000 to 160,000 individuals worldwide. The condition is more common in certain genetically isolated populations: 1 in 75 in a small group of Jews who immigrated to Israel from southern Arabia (Habbanites), 1 in 2,500 in the western portion of the Navajo Nation, and 1 in 8,000 among Arab groups in Israel.

Genetic Changes

Most individuals with metachromatic leukodystrophy have mutations in the *ARSA* gene, which provides instructions for making the enzyme arylsulfatase A. This enzyme is located in cellular structures called lysosomes, which are the cell's recycling centers. Within lysosomes, arylsulfatase A helps break down sulfatides. A few individuals with metachromatic leukodystrophy have mutations in the *PSAP* gene. This gene provides instructions for making a protein that is broken up (cleaved) into smaller proteins that assist enzymes in breaking down various fats. One of these smaller proteins is called saposin B; this protein works with arylsulfatase A to break down sulfatides.

Mutations in the *ARSA* or *PSAP* genes result in a decreased ability to break down sulfatides, resulting in the accumulation of these substances in cells. Excess sulfatides are toxic to the nervous system. The accumulation gradually destroys myelin-producing cells, leading to the impairment of nervous system function that occurs in metachromatic leukodystrophy.

In some cases, individuals with very low arylsulfatase A activity show no symptoms of metachromatic leukodystrophy. This condition is called pseudoarylsulfatase deficiency.

Inheritance Pattern

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

- ARSA deficiency
- arylsulfatase A deficiency disease

- cerebral sclerosis, diffuse, metachromatic form
- cerebroside sulphatase deficiency disease
- Greenfield disease
- metachromatic leukoencephalopathy
- MLD
- sulfatide lipidosis
- sulfatidosis

Diagnosis & Management

These resources address the diagnosis or management of metachromatic leukodystrophy:

- GeneReview: Arylsulfatase A Deficiency
<https://www.ncbi.nlm.nih.gov/books/NBK1130>
- Genetic Testing Registry: Metachromatic leukodystrophy
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0023522/>
- Genetic Testing Registry: Sphingolipid activator protein 1 deficiency
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0268262/>

These resources from MedlinePlus offer information about the diagnosis and management of various health conditions:

- Diagnostic Tests
<https://medlineplus.gov/diagnostictests.html>
- Drug Therapy
<https://medlineplus.gov/drugtherapy.html>
- Surgery and Rehabilitation
<https://medlineplus.gov/surgeryandrehabilitation.html>
- Genetic Counseling
<https://medlineplus.gov/geneticcounseling.html>
- Palliative Care
<https://medlineplus.gov/palliativecare.html>

Additional Information & Resources

MedlinePlus

- Health Topic: Leukodystrophies
<https://medlineplus.gov/leukodystrophies.html>

Genetic and Rare Diseases Information Center

- Metachromatic leukodystrophy
<https://rarediseases.info.nih.gov/diseases/3230/metachromatic-leukodystrophy>

Additional NIH Resources

- NINDS Metachromatic Leukodystrophy Information Page
<https://www.ninds.nih.gov/Disorders/All-Disorders/Metachromatic-leukodystrophy-Information-Page>

Educational Resources

- Disease InfoSearch: Metachromatic leukodystrophy
<http://www.diseaseinfosearch.org/Metachromatic+leukodystrophy/4691>
- MalaCards: metachromatic leukodystrophy
http://www.malacards.org/card/metachromatic_leukodystrophy
- Orphanet: Metachromatic leukodystrophy
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=512
- The MPS Society (UK): Guide to Metachromatic Leukodystrophy
<http://www.mpsociety.org.uk/wp-content/uploads/2016/07/guide-mld-2013.pdf>

Patient Support and Advocacy Resources

- Children Living with Inherited Metabolic Diseases
<http://www.climb.org.uk/>
- Hunter's Hope Foundation
<http://www.huntershope.org/site/PageServer>
- MLD Foundation
<http://mldfoundation.org/>
- National Organization for Rare Disorders
<https://rarediseases.org/rare-diseases/metachromatic-leukodystrophy/>
- National Tay-Sachs and Allied Diseases Association
<https://www.ntsad.org/>
- The MPS Society (UK)
<http://www.mpsociety.org.uk/diseases/related-diseases/metachromatic-leukodystrophy/>
- United Leukodystrophy Foundation
<http://ulf.org/>

GeneReviews

- Arylsulfatase A Deficiency
<https://www.ncbi.nlm.nih.gov/books/NBK1130>

Genetic Testing Registry

- Metachromatic leukodystrophy
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0023522/>
- Sphingolipid activator protein 1 deficiency
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0268262/>

ClinicalTrials.gov

- ClinicalTrials.gov
<https://clinicaltrials.gov/ct2/results?cond=%22metachromatic+leukodystrophy%22>

Scientific articles on PubMed

- PubMed
<https://www.ncbi.nlm.nih.gov/pubmed?term=%28Leukodystrophy,+Metachromatic%5BMAJR%5D%29+AND+%28metachromatic+leukodystrophy%5BTIAB%5D%29+AND+english%5BIa%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D>

OMIM

- METACHROMATIC LEUKODYSTROPHY
<http://omim.org/entry/250100>
- METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY
<http://omim.org/entry/249900>

Sources for This Summary

- Al-Hassnan ZN, Al Dhalaan H, Patay Z, Fageih E, Al-Owain M, Al-Duraihem A, Faiyaz-UI-Haque M. Sphingolipid activator protein B deficiency: report of 9 Saudi patients and review of the literature. *J Child Neurol.* 2009 Dec;24(12):1513-9. doi: 10.1177/0883073809341269. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/19955343>
- Artigalás O, Lagranha VL, Saraiva-Pereira ML, Burin MG, Lourenço CM, van der Linden H Jr, Santos ML, Rosemberg S, Steiner CE, Kok F, de Souza CF, Jardim LB, Giugliani R, Schwartz IV. Clinical and biochemical study of 29 Brazilian patients with metachromatic leukodystrophy. *J Inher Metab Dis.* 2010 Dec;33 Suppl 3:S257-62. doi: 10.1007/s10545-010-9140-4. Epub 2010 Jul 2.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/20596894>
- Deconinck N, Messaoui A, Zierysen F, Kadhim H, Sznajer Y, Pelc K, Nassogne MC, Vanier MT, Dan B. Metachromatic leukodystrophy without arylsulfatase A deficiency: a new case of saposin-B deficiency. *Eur J Paediatr Neurol.* 2008 Jan;12(1):46-50. Epub 2007 Jul 5.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/17616409>

- GeneReview: Arylsulfatase A Deficiency
<https://www.ncbi.nlm.nih.gov/books/NBK1130>
- Gieselmann V, Krägeloh-Mann I. Metachromatic leukodystrophy--an update. *Neuropediatrics*. 2010 Feb;41(1):1-6. doi: 10.1055/s-0030-1253412. Epub 2010 Jun 22. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/20571983>
- Grossi S, Regis S, Rosano C, Corsolini F, Uziel G, Sessa M, Di Rocco M, Parenti G, Deodato F, Leuzzi V, Biancheri R, Filocamo M. Molecular analysis of ARSA and PSAP genes in twenty-one Italian patients with metachromatic leukodystrophy: identification and functional characterization of 11 novel ARSA alleles. *Hum Mutat*. 2008 Nov;29(11):E220-30. doi: 10.1002/humu.20851.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/18693274>
- OMIM: METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY
<http://omim.org/entry/249900>
- Poeppel P, Habetha M, Marcão A, Büsow H, Berna L, Gieselmann V. Missense mutations as a cause of metachromatic leukodystrophy. Degradation of arylsulfatase A in the endoplasmic reticulum. *FEBS J*. 2005 Mar;272(5):1179-88.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/15720392>
- Rauschka H, Colsch B, Baumann N, Wevers R, Schmidbauer M, Krammer M, Turpin JC, Lefevre M, Olivier C, Tardieu S, Krivit W, Moser H, Moser A, Gieselmann V, Zalc B, Cox T, Reuner U, Tytki-Szymanska A, Aboul-Enein F, LeGuern E, Bernheimer H, Berger J. Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype. *Neurology*. 2006 Sep 12;67(5):859-63.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/16966551>
- Rodriguez-Waitkus PM, Byrd R, Hicks J. Metachromatic leukodystrophy and its effects on the gallbladder: a case report. *Ultrastruct Pathol*. 2011 Dec;35(6):271-6. doi: 10.3109/01913123.2011.620730.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/22085303>

Reprinted from Genetics Home Reference:

<https://ghr.nlm.nih.gov/condition/metachromatic-leukodystrophy>

Reviewed: February 2013

Published: January 24, 2017

Lister Hill National Center for Biomedical Communications

U.S. National Library of Medicine

National Institutes of Health

Department of Health & Human Services